Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.
Saved in:
| Title: | Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms. |
|---|---|
| Authors: | Watts J; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Minden MD; Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada., Bachiashvili K; Division of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA., Brunner AM; Leukemia Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Abedin S; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Crossman T; Oncology Clinical Development, GSK, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK., Zajac M; Oncology Clinical Development, GSK, London, UK., Moroz V; Biostatistics, GSK, Stevenage, UK., Egger JL; Oncology Clinical Development, GSK, London, UK., Tarkar A; Oncology Clinical Development, GSK, Collegeville, PA, USA., Kremer BE; Oncology Clinical Development, GSK, Collegeville, PA, USA., Barbash O; Oncology Clinical Development, GSK, Collegeville, PA, USA., Borthakur G; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | Therapeutic advances in hematology [Ther Adv Hematol] 2024 Sep 14; Vol. 15, pp. 20406207241275376. Date of Electronic Publication: 2024 Sep 14 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101549589 Publication Model: eCollection Cited Medium: Print ISSN: 2040-6207 (Print) Linking ISSN: 20406207 NLM ISO Abbreviation: Ther Adv Hematol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2040-6207 |
|---|---|
| DOI: | 10.1177/20406207241275376 |
